“This study provides potentially lifesaving information that will be useful to health care providers as they consider the best treatment options for some of their patients, particularly those over the age of 50,” said Gary H. Gibbons, M.D., director of the National Heart, Lung, and Blood Institute (NHLBI), the primary sponsor of SPRINT. “We are delighted to have achieved this important milestone in the study in advance of the expected closure date for the SPRINT trial and look forward to quickly communicating the results to help inform patient care and the future development of evidence-based clinical guidelines.”
High blood pressure, or hypertension, is a leading risk factor for heart disease, stroke, kidney failure, and other health problems. An estimated 1 in 3 people in the United States has high blood pressure.
The SPRINT study, which was sponsored by the NIH, evaluates the benefits of maintaining a new target for systolic blood pressure, the top number in a blood pressure reading, among a group of patients 50 years and older at increased risk for heart disease or who have kidney disease. A systolic pressure of 120 mm Hg, maintained by this more intensive blood pressure intervention, could ultimately help save lives among adults age 50 and older who have a combination of high blood pressure and at least one additional risk factor for heart disease, the investigators say.
Wake Forest Baptist Medical Center is the national Coordinating Center for the SPRINT clinical trial and also heads one of the five networks conducting the trial. David Reboussin, Ph.D., professor of public health sciences, is principal investigator for the Coordinating Center; Kaycee Sink, M.D., acting section chief of gerontology and geriatric medicine, is the Safety Officer for the trial; Michael Rocco, M.D., professor of nephrology, is the principal investigator for the Wake Forest Baptist network (Southeast Network); and Jeff Williamson, M.D., acting chair of internal medicine, is leading aspects of SPRINT focused on seniors (persons over age 75), as well as the ongoing SPRINT investigation of the effects on cognition and development of dementia.
The SPRINT study, which began in the fall of
2009, includes more than 9,300 participants age 50 and older, recruited from
about 100 medical centers and clinical practices throughout the United States
and Puerto Rico. It is the largest study of its kind to date to examine how
maintaining systolic blood pressure at a lower than currently recommended level
will impact cardiovascular and kidney diseases. NIH stopped the blood pressure
intervention earlier than originally planned in order to quickly disseminate
the significant preliminary results.
The study population was diverse and included women, racial/ethnic minorities, and the elderly. The investigators point out that the SPRINT study did not include patients with diabetes, prior stroke, or polycystic kidney disease, as other research included those populations.
When SPRINT was designed, the well-established clinical guidelines recommended a systolic blood pressure of less than 140 mm Hg for healthy adults and 130 mm Hg for adults with kidney disease or diabetes. Investigators designed SPRINT to determine the potential benefits of achieving systolic blood pressure of less than 120 mm Hg for hypertensive adults 50 years and older who are at risk for developing heart disease or kidney disease.
Between 2010 and 2013, the SPRINT investigators randomly divided the study participants into two groups that differed according to targeted levels of blood pressure control. The standard group received blood pressure medications to achieve a target of less than 140 mm Hg. They received an average of two different blood pressure medications. The intensive treatment group received medications to achieve a target of less than 120 mm Hg and received an average of three medications.
“Our results provide important evidence that treating blood pressure to a lower goal in older or high-risk patients can be beneficial and yield better health results overall,” said Lawrence Fine, M.D., chief, Clinical Applications and Prevention Branch at NHLBI. “But patients should talk to their doctor to determine whether this lower goal is best for their individual care.”
The study is also examining kidney disease, cognitive function, and dementia among the patients; however, those results are still under analysis and are not yet available as additional information will be collected over the next year. The primary results of the trial will be published within the next few months.
In addition to primary sponsorship by the NHLBI, SPRINT is co-sponsored by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, and the National Institute on Aging.
Marguerite Beck: email@example.com, 336-716-2415